Lamotrigine Therapy in Infantile Neuronal Ceroid Lipofuscinosis (INCL)

Laura Åberg; H. Heiskala; S.-L. Vanhanen; J. J. Himberg; G. Hosking; A. Yuen; P. Santavuori

doi:10.1055/s-2007-973676

Neuropediatrics, Table of Contents

Neuropediatrics 1997; 28(1): 77-79
DOI: 10.1055/s-2007-973676

Short communications

Lamotrigine Therapy in Infantile Neuronal Ceroid Lipofuscinosis (INCL)

Laura Åberg¹ , H. Heiskala² , S.-L. Vanhanen¹ , J. J. Himberg¹ , G. Hosking³ , A. Yuen³ , P. Santavuori¹

¹Children's Hospital, Pediatric Neurology, University of Helsinki,
²Rinnekoti Foundation, Espoo
³Glaxo Wellcome

Abstract

PDF Download

Abstract

Since 1990, altogether 16 INCL patients received lamotrigine (LTG) because of intractable epilepsy. The response to LTC was favorable in 15/16 children. The severity of seizures decreased significantly in 15/16 patients, the frequency of seizures decreased in 14/16, and the effects were maintained. In addition, LTC had a beneficial effect on the wellbeing of 14/16 children. LTC failed to maintain it's efficacy in monotherapy. No severe side effects were found.

Key words

Infantile neuronal ceroid lipofuscinosis - Lamotrigine - Epilepsy

PDF (323 kb)